Regeneron

Today we announced a strategic research collaboration with Parabilis Medicines that combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform. The collaboration aims to discover and develop multiple therapeutic candidates based on Parabilis’ Helicon™ peptide platform, with a particular focus on Antibody-Helicon™ Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically “undruggable” targets. The agreement reflects Regeneron’s approach of advancing cutting-edge and diversified science to produce a robust portfolio of innovative medicines for patients in need. Read more: https://bit.ly/4wyoeEW 

🌍 Meet the winners of the Regeneron International Science and Engineering Fair (ISEF)! This week, the world’s top young STEM leaders came together in Phoenix, Arizona for ISEF, a program of Society for Science and the world’s largest STEM competition for high school students, competing for nearly $7 million in awards and scholarships. Selected from thousands of outstanding students around the globe, these finalists and winners are being recognized for bold research that showcases innovation, ingenuity, and the potential to tackle some of the world’s most pressing challenges. Congratulations to this year’s finalists and winners. We cannot wait to see where your ideas lead next. 💡✨ 👉 Learn more about the 2026 Regeneron ISEF winners: https://bit.ly/3PkUJpC #RegeneronSTEMFueled

At #STATBreakthrough Summit East, leaders explored what it takes to move from scientific possibility to impact, with an emphasis on the data foundations behind innovation.     Gonçalo Abecasis, Regeneron Genetics Center’s SVP and Chief Genomics and Data Science Officer, joined STAT’s Damian Garde to discuss AI-driven genomic research and how data quality and scale can be more influential than model choice.     Thank you to STAT and to everyone who made this event energizing and insightful. Watch the discussion below and learn more here: https://bit.ly/3PmY5bA  #HealthInnovation

Science is how we make the greatest impact, and it’s at the heart of our new responsibility strategy. We are advancing innovation responsibly with goals like continuing to build Regeneron Genetics Center (RGC)’s world-class proteogenomic data resource to deliver insights that transform healthcare, sequencing 10M samples and integrating AI and big data tools to strengthen drug discovery and digital health solutions. Because how we advance science matters just as much as how far it takes us. Explore our 2030 goals: https://bit.ly/42uCsJm

The bottleneck was in the model. One-gene-at-a-time editing in traditional mice could not capture the complexity of the human immune system, which slowed discovery efforts.     Using VelociGene®, our platform for large-scale DNA editing, we engineered mice with fully human immune systems. The work reflects principles set by our co-founder and CSO, George D. Yancopoulos, to focus on scalable, precise genetics that translate to patients.    This approach helps remove key obstacles in antibody discovery and development. Watch to learn how we did it and why it matters for patients. https://bit.ly/4uuFoS8

For the seventh consecutive year, we have been named to the S&P Global Dow Jones Best-in-Class World Index, and for the sixth consecutive year, to the North America Index, in recognition of our global responsibility leadership.     As one of the few biotechnology companies recognized, this milestone reflects our longstanding commitment to embed responsibility into every aspect of our business, from how we discover groundbreaking medicines to how we operate as a company.     This recognition follows the release of our 2025 Responsibility Report, which details our progress and introduces new, science-led 2030 responsibility goals to drive responsible innovation for years to come.     Read the full announcement: https://bit.ly/4wjG3aN   #DJBIC #sustainability

What’s it like to share a stage with brilliant young STEM leaders from more than 60 countries?    As we count down to this year’s Regeneron International Science and Engineering Fair (ISEF), we’re reflecting on what last year’s finalists and judges shared. The friendships made across continents. The research reshaped by perspectives they hadn’t encountered before. The realization that work begun in a school lab can matter on a global scale.    ISEF, a program of Society for Science, is the world’s largest international science competition for high school students. We can’t wait to welcome this year’s finalists and to see once again why it’s so much more than a competition.   Lear more about ISEF: https://bit.ly/4tTORml     #STEMFueled #RegeneronSTEMFueled 

Celebrating a decade of impact. 🎉 Since 2017, more than 80 colleagues across our global sites have been recognized for their dedication to strengthening communities through volunteerism —  sustained commitment that drives meaningful societal change. Congrats to this year’s Volunteers of the Year Award honorees. Your work shows us what’s possible when we truly live “doing well by doing good.”

Regeneron’s longstanding philosophy of “Doing Well by Doing Good” reflects the belief that breakthrough science and responsible business practices go hand in hand to improve lives.    Our new science-led corporate responsibility strategy serves as our compass in creating a healthier world. It is made up of four pillars, with ethics and integrity as the thread that connects them:   🔬 Science   ❤️ Access   👥 People   🌱 Planet      This builds on our strong progress and the completion of our 2025 goals, as highlighted in our newly published 2025 Responsibility Report. Learn more: https://bit.ly/4uhlMkn

Pushing the boundaries of what’s possible in science is at the core of what we do, and Q1 2026 reflected that commitment in meaningful ways for patients. Today we reported our first quarter financial and operating results, reflecting continued momentum across our pipeline, portfolio and broader work to expand patient access. Q1 2026 and Recent Highlights 🌟Received FDA approval for our first gene therapy, the first and only treatment for an ultra-rare form of genetic hearing loss in children, which we are proud to provide for free in the U.S.  ✍️ Reached an agreement with the U.S. government to help lower drug costs for American patients while preserving the innovation that drives new medicines  🌍 Secured new approvals and regulatory recommendations across dermatology, immunology and rare disease in the U.S., EU and Japan 🧬 Advanced our pipeline with a Priority Review acceptance for a potential first treatment for adults with an ultra-rare and progressively disabling bone disorder 🤝 Expanded our research efforts through strategic collaborations with Telix Pharmaceuticals to co-develop next-generation radiopharmaceutical therapies, and with TriNetX to access de-identified electronic health records of 300 million patients to accelerate research and product development 🎓 Renewed our sponsorship of the Regeneron Science Talent Search through 2036 with an additional $150M commitment, continuing our partnership with the Society for Science to support the nation's oldest and most prestigious science and math competition for high school seniors Thank you to our colleagues, collaborators, investigators and patients who make it all happen.  Read more: https://bit.ly/4ecsovE